NeoGenomics, Inc. (NEO): Price and Financial Metrics

NeoGenomics, Inc. (NEO): $47.49

1.30 (+2.81%)

POWR Rating

Component Grades














  • Momentum is the dimension where NEO ranks best; there it ranks ahead of 46.52% of US stocks.
  • NEO's strongest trending metric is Sentiment; it's been moving down over the last 31 weeks.
  • NEO ranks lowest in Sentiment; there it ranks in the 4th percentile.

NEO Stock Summary

  • Price to trailing twelve month operating cash flow for NEO is currently 500.49, higher than 99.21% of US stocks with positive operating cash flow.
  • With a year-over-year growth in debt of 281.19%, Neogenomics Inc's debt growth rate surpasses 96.22% of about US stocks.
  • In terms of twelve month growth in earnings before interest and taxes, Neogenomics Inc is reporting a growth rate of -546.69%; that's higher than only 3.46% of US stocks.
  • If you're looking for stocks that are quantitatively similar to Neogenomics Inc, a group of peers worth examining would be SDGR, DRRX, ELSE, SRCL, and EEFT.
  • Visit NEO's SEC page to see the company's official filings. To visit the company's web site, go to

NEO Valuation Summary

  • NEO's price/sales ratio is 11.9; this is 230.56% higher than that of the median Healthcare stock.
  • NEO's EV/EBIT ratio has moved down 228.6 over the prior 211 months.
  • Over the past 211 months, NEO's price/sales ratio has gone down 9.5.

Below are key valuation metrics over time for NEO.

Stock Date P/S P/B P/E EV/EBIT
NEO 2019-05-14 7.1 6.7 371.9 473.4
NEO 2018-12-17 4.4 3.8 146.1 101.7
NEO 2018-05-01 3.1 4.6 -70.5 435.2
NEO 2015-10-14 3.6 5.7 -1915.5 454.1
NEO 2010-11-15 1.4 13.9 -10.5 -13.8
NEO 2005-08-19 10.8 -18.4 -10.3 -12.0

NEO Growth Metrics

  • The 4 year net cashflow from operations growth rate now stands at -27.39%.
  • Its 2 year revenue growth rate is now at 61.04%.
  • Its 4 year price growth rate is now at 271.94%.
NEO's revenue has moved up $45,121,000 over the prior 15 months.

The table below shows NEO's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 453.951 10.603 -10.964
2020-12-31 444.448 1.46 4.172
2020-09-30 425.319 -1.166 -4.949
2020-06-30 404.547 16.942 -5.363
2020-03-31 419.283 10.339 3.452
2019-12-31 408.83 23.369 8.006

NEO Price Target

For more insight on analysts targets of NEO, see our NEO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $57.27 Average Broker Recommendation 1.31 (Strong Buy)

NEO Stock Price Chart Interactive Chart >

Price chart for NEO

NEO Price/Volume Stats

Current price $47.49 52-week high $61.57
Prev. close $46.19 52-week low $34.18
Day low $46.06 Volume 558,400
Day high $47.53 Avg. volume 834,206
50-day MA $43.85 Dividend yield N/A
200-day MA $47.28 Market Cap 5.60B

NeoGenomics, Inc. (NEO) Company Bio

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories providing genetic and molecular testing services to hospitals, pathologists, oncologists, urologists, other clinicians and researchers, and other laboratories in the United States. The company was founded in 2001 and is based in Fort Myers, Florida.

NEO Latest News Stream

Event/Time News Detail
Loading, please wait...

NEO Latest Social Stream

Loading social stream, please wait...

View Full NEO Social Stream

Latest NEO News From Around the Web

Below are the latest news stories about Neogenomics Inc that investors may wish to consider to help them evaluate NEO as an investment opportunity.

Earnings Preview: NeoGenomics (NEO) Q2 Earnings Expected to Decline

NeoGenomics (NEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | July 30, 2021

Bear of the Day: NeoGenomics (NEO)

Emerging diagnostics provider is steadily growing sales and key M&A but ran into an EPS cliff

Yahoo | July 30, 2021

7 Growth Stocks to Buy As Meme Stock Mania Fades

As the craze for meme stocks fades away, investors should consider growth investing to generate big returns.

Tezcan Gecgil on InvestorPlace | July 19, 2021

The Trade Desk Has More Gas in the Tank Despite Frothy Valuation 

I recently suggested The Trade Desk (NASDAQ:TTD) would do well in the second half of 2021.

Will Ashworth on InvestorPlace | July 19, 2021

Inivata Acquisition Injects NeoGenomics with Growth Potential

The premier cancer diagnostics and pharma services company NeoGenomics (NASDAQ: NEO) has been in the headlines lately. NeoGenomics serves oncologists, pathologists, pharmaceutical companies, academic centers, and others with innovative diagnostic, prognostic, and predictive testing. The company provides oncology-focused testing methodologies and platforms to help physicians to diagnose and treat cancer. Recently, the company combined its cancer-focused research and testing services with best-in-class liquid biopsy technology, through its acquisition of England-based Inivata Ltd. Inivata is a global, commercial-stage liquid biopsy platform company. Over the past year, NeoGenomics stock has increased 28%.

Priti Ramgarhia on TipRanks | July 14, 2021

Read More 'NEO' Stories Here

NEO Price Returns

1-mo 5.82%
3-mo 15.58%
6-mo -13.65%
1-year 17.78%
3-year 219.37%
5-year 482.70%
YTD -11.79%
2020 84.07%
2019 131.96%
2018 42.33%
2017 3.38%
2016 8.89%

Continue Researching NEO

Here are a few links from around the web to help you further your research on Neogenomics Inc's stock as an investment opportunity:

Neogenomics Inc (NEO) Stock Price | Nasdaq
Neogenomics Inc (NEO) Stock Quote, History and News - Yahoo Finance
Neogenomics Inc (NEO) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.7828 seconds.